Skip to main content

Advertisement

Table 1 Patient and mapping characteristics

From: The variability of motor evoked potential latencies in neurosurgical motor mapping by preoperative navigated transcranial magnetic stimulation

  Male Female All
Number of patients 57 43 100
Age at exam (in years) 54.0 ± 13.9
(20–83)
54.2 ± 15.7
(19–84)
54.1 ± 14.7
(19–84)
AEDs    
 NA 26 27 53
 L 19 11 30
 SA 4 1 5
 NK 5 3 8
 UA 3 1 4
Motor deficit    
 ND 41 31 72
 D 16 12 28
Tumor location    
 RO 19 16 35
 FR 15 9 24
 PA 11 8 19
 PoG 11 6 17
 TE 1 4 5
Tumor side    
 LH 23 17 40
 RH 34 26 60
Dominancy    
 NDO 28 25 53
 DO 26 16 42
Edema    
 NE 37 31 68
 E 20 12 32
Tumor entity    
 II 8 6 14
 III 4 6 10
 IV 21 17 38
 ME 14 11 25
 X 10 3 13
Tumor recurrence    
 NR 44 34 78
 R 13 9 22
Tumor volume (in cm3) 27.2 ± 5.4 (19.9–42.9) 26.1 ± 5.0 (20.3–39.9) 26.7 ± 5.2 (19.9–42.9)
rMT (in %) 31.9 ± 7.5 (20–59) 36.4 ± 10.6 (22–72) 33.8 ± 9.3 (20–72)
Year of mapping    
 Y10 13 16 29
 Y11 14 6 20
 Y12 10 5 15
 Y13 20 16 36
  1. Overview on patient and mapping characteristics by gender, including age at exam, antiepileptics (AEDs: NA  no AED, L levetiracetam, SA other specified AEDs, NK AED status not known, UA unspecified AEDs), and presence of motor deficits (ND no deficit, D deficit). Furthermore, tumor location (RO Rolandic, FR frontal, PA parietal, PoG postcentral gyrus, TE temporal), tumor side (LH left hemisphere, RH right hemisphere), dominancy of the tumor hemisphere (NDO non-dominant, DO dominant), tumor-related edema (NE no edema, E edema), tumor entity (II astrocytoma WHO grade II, III astrocytoma WHO grade III, IV astrocytoma WHO grade IV, ME metastasis, other entities), tumor recurrence (NR no recurrence, R recurrence), and tumor volume are displayed. In addition, resting motor threshold (rMT) values and year of mapping (Y10 exam year 2010, Y11 exam year 2011, Y12 exam year 2012, Y13 exam year 2013) are shown. All values are presented as number of patients, mean ± standard deviation (SD), or ranges. Dominancy data do not add up to 100 patients since it was not assessed in five patients